Please login to the form below

Not currently logged in
Email:
Password:

gene therapy

This page shows the latest gene therapy news and features for those working in and with pharma, biotech and healthcare.

Axovant drops last ‘legacy’ drug to focus on gene therapies

Axovant drops last ‘legacy’ drug to focus on gene therapies

back from that approach and re-inventing itself as a gene therapy player, once again by licensing rights to technologies developed at other companies. ... licensed rights to a gene therapy for Parkinson’s disease (PD) from UK biotech Oxford BioMedica

Latest news

  • FDA fast tracks Novartis’ SMA gene therapy FDA fast tracks Novartis’ SMA gene therapy

    Gene therapy could be approved in first half of 2019, will challenge Biogen's Spinraza. ... require just one infusion of the gene therapy, rather than the long-term treatment required with Spinraza.

  • Astellas makes another gene therapy play with Juventas deal Astellas makes another gene therapy play with Juventas deal

    Targeting faecal incontinence, which affects 50m worldwide. Astellas has made another deal in the gene therapy category, licensing a candidate for treating faecal incontinence from US biotech Juventas Therapeutics. ... The Japanese drugmaker has been

  • Digital tech from Autolus and Oxford BioMedica to speed advanced therapies Digital tech from Autolus and Oxford BioMedica to speed advanced therapies

    UK funds efforts to make country a leader in cell and gene therapy. ... The London-based company is developing its own next-generation CAR-T treatments, and has been supported by the government-funded Cell and Gene Therapy Catapult.

  • UniQure skyrockets on haemophilia B gene therapy data UniQure skyrockets on haemophilia B gene therapy data

    Competition with Pfizer and Spark rival heats up. It’s a measure of the anticipation about gene therapy that data positive data in three haemophilia patients caused UniQure shares to close ... Another emerging competitor is UK start-up Freeline

  • Duchenne UK backs Evox dystrophin delivery project Duchenne UK backs Evox dystrophin delivery project

    Duchenne UK’s co-CEOs Emily Crossley &Alex Johnson said that Evox’s technology may also help overcome one of the problems with gene therapy, namely that patients can have ... existing antibodies primed to respond to the viruses used to deliver the

More from news
Approximately 37 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    In Ciba-Geigy/Sandoz, the FTC was concerned that the merger could impair the development of gene therapy, a market that the FTC forecast to be worth US$45bn within 20 years ... Although the parties divested one of the gene therapy programmes to Aventis,

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Pfizer also has a considerable stake in one of the most exciting emerging areas of innovation, cell and gene therapy. ... It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe. ... drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... This, and near-perpetual reform, continues to confound

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Niels Ryber Finsen received the accolade for his pioneering ultraviolet light therapy in 1903 and experts in the field believe it is time the spotlight was once again turned on the ... The Leo surge will include gene therapy and the flexibility to push

More from intelligence
Approximately 2 fully matching, plus 33 partially matching documents found.

Latest appointments

  • Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

    Orchard Therapeutics expands leadership team. Gene therapy focused Orchard Therapeutics has announced two new additions to its executive leadership team.

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    Francois Nader joins the biotech. Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition ... advance our pipeline

  • Abeona Therapeutics appoints new additions to board of directors Abeona Therapeutics appoints new additions to board of directors

    He said: “Abeona’s ambitious gene and cell therapies have the promise to bring treatments to patients for whom there are currently no treatment options available. ... He said: “I am excited to be joining Abeona’s board at such a time of momentum

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    Dr Bekkali’s previous leadership positions include global head of the ophthalmology business unit at Sanofi, where she led its ophthalmology strategy towards ocular gene therapy and set up a multidisciplinary ... team. Chris Hollowood, chairman of the

More from appointments
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics